In obstetrics, aspirin is commonly prescribed for conditions such as preeclampsia and antiphospholipid syndrome. The usual dosage is 75 to 150 milligrams per day. It can cross the placenta and often used continuously during the entire pregnancy. Although high-dose animal studies have reported the developmental toxicities including neural tube defects and other structural abnormalities, the effects of plasma-level aspirin concentrations on embryogenesis remain poorly understood. In this study, we exposed zebrafish embryos to plasma - level concentrations of aspirin and observed dose-dependent decreases in heart rate, body length and locomotor activity ( measured by movement speed and distance), all changes were statistically significant. Additionally, the incidence of curled tails exhibited an upward trend, though it did not achieve statistical significance. In situ hybridization, transcriptomic, and epigenomic analyses revealed neurodevelopmental, muscular, cardiovascular, and renal abnormalities consistent with those reported in related studies. This paper outlines potential mechanisms linking differentially expressed genes and molecular modifications, providing a novel reference for evaluating the potential impacts of plasma - level aspirin concentrations on fetal development and guiding its clinical use during pregnancy.